Langer-in­spired Kala files for an $86M IPO; J&J backs Proven­tion Bio

→  Kala Phar­ma­ceu­ti­cals has filed for an $86 mil­lion IPO, just weeks af­ter the biotech re­port­ed pos­i­tive top line da­ta for a Phase III study of its lead oph­thal­mol­o­gy drug KPI-121. In its S-1 the biotech — co-found­ed by MIT’s Bob Langer — says that it will file its first NDA be­fore the end of this year, with an­oth­er to fol­low in ear­ly 2018. And it’s in two more Phase III stud­ies for dry eye dis­ease with an­oth­er for­mu­la­tion of the lead treat­ment. Kala has tried to pull off an IPO dur­ing try­ing times for biotech stocks. Now the mar­ket has been boom­ing for a few days at least and biotech IPOs have been lin­ing up to take ad­van­tage of grow­ing ev­i­dence that in­vestors are once again in­vest­ing in risky plays.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.